Stalevo (Lyfjaver) Filmuhúðuð tafla 100 mg/25 mg/200 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

stalevo (lyfjaver) filmuhúðuð tafla 100 mg/25 mg/200 mg

lyfjaver ehf. - entacaponum inn; levodopum inn; carbidopum inn - filmuhúðuð tafla - 100 mg/25 mg/200 mg

Penovet vet. Stungulyf, dreifa 300 .000 a.e./ml Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

penovet vet. stungulyf, dreifa 300 .000 a.e./ml

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml

Diprospan Stungulyf, dreifa 5+2 mg/ml Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

diprospan stungulyf, dreifa 5+2 mg/ml

n.v. organon* - betamethasonum dínatríumfosfat; betamethasonum díprópíónat - stungulyf, dreifa - 5+2 mg/ml

Otrason (Flixonase) Nefúði, dreifa 50 míkróg/skammt Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

otrason (flixonase) nefúði, dreifa 50 míkróg/skammt

haleon denmark aps - fluticasonum própíónat - nefúði, dreifa - 50 míkróg/skammt

Tradolan Filmuhúðuð tafla 50 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

tradolan filmuhúðuð tafla 50 mg

g.l. pharma gmbh - tramadolum hýdróklóríð - filmuhúðuð tafla - 50 mg

Xonvea Magasýruþolin tafla 10 mg/10 mg Islandija - islandščina - LYFJASTOFNUN (Icelandic Medicines Agency)

xonvea magasýruþolin tafla 10 mg/10 mg

campuspharma ab - pyridoxinum hýdróklóríð; doxylaminii hýdrógen súkkínat - magasýruþolin tafla - 10 mg/10 mg

Sutent Evropska unija - islandščina - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.